RNTX — Rein Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1420565 ·
Last close
$0.36
Market Cap
$30.75M
52W High
$2.10
52W Low
$0.28
ADV30
743,853
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -6,999,000 | -5,537,000 | 59,430,000 | 943,000 | 51,663,000 |
| Jun 2026 | 0 | — | -6,076,000 | -6,375,000 | 65,973,000 | 8,542,000 | 55,774,000 |
| Mar 2026 | 0 | — | -5,230,000 | -5,838,000 | 26,288,000 | 4,445,000 | 59,702,000 |
| Dec 2025 | 0 | — | -3,959,000 | -31,967,000 | 24,158,000 | 3,215,000 | 52,245,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,832,000
Investing CF
—
Financing CF
$56,774,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.78
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-413,484,000
Inventory
—
Receivables
—
ST Investments
$32,105,000
EBIT TTM
$-20,757,000
Pretax Income TTM
$-50,473,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -21,931,000 | -49,871,000 | 24,158,000 | 52,245,000 | -28,087,000 | -19,361,000 |
| Dec 2024 | 0 | -28,112,000 | -62,883,000 | 62,190,000 | 52,803,000 | 9,387,000 | -22,291,000 |
| Dec 2023 | 0 | -15,348,000 | -15,732,000 | 106,008,000 | 99,121,000 | 6,887,000 | -19,808,000 |
| Dec 2022 | 0 | -27,647,000 | -27,329,000 | 22,007,000 | 3,384,000 | 18,623,000 | -24,865,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-49,761,000
OpCashFlow TTM
—
Assets (Latest)
$65,973,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NXTC | NextCure, Inc. | $30.68M | $6.70 | — |
| BCTX | BriaCell Therapeutics Corp. | $30.65M | $3.51 | — |
| NSRX | Nasus Pharma Ltd | $30.57M | $2.61 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $31.17M | $0.42 | — |
| RLFTY | MindMaze Therapeutics Holding SA | $30.24M | $0.18 | — |
News headlines (Yahoo Finance, 1h cache)
Rein reports early Phase II data for inhaled IPF drug
2026-11-17 10:08 · Yahoo
Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Resu
2026-11-16 12:30 · Yahoo
Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-02 13:00 · Yahoo
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
2026-09-04 12:00 · Yahoo
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
2026-08-20 12:00 · Yahoo
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-14 10:44 · Yahoo
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
2026-08-04 12:00 · Yahoo
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
2026-07-21 12:00 · Yahoo
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
2026-04-29 12:00 · Yahoo
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
2026-05-01 00:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.